Skip to main content

Table 3 Adverse events

From: Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

AEs, n (%)

G1

G2

G3

G4

G3 + 4

All

Leukopenia

2 (6.3)

13 (40.6)

10 (31.3)

3 (9.4)

13 (40.6)

28 (87.5)

Neutropenia

1 (3.1)

5 (15.6)

8 (25)

14 (43.8)

22 (68.8)

28 (87.5)

Thrombocytopenia

14 (43.8)

2 (6.3)

1 (3.1)

0

1 (3.1)

17 (53.1)

Anemia

15 (46.9)

10 (31.3)

0

0

0

25 (78.1)

Febrile Neutropenia

0

0

3 (9.4)

0

3 (9.4)

3 (9.4)

Peripheral Neuropathy

0

9 (28.1)

4 (12.5)

0

4 (12.5)

13 (40.6)

Constipation

0

3 (9.4)

0

0

0

3 (9.4)

Dysgeusia

0

5 (15.6)

0

0

0

5 (15.6)

Fatigue

0

2 (6.3)

1 (3.1)

0

1 (3.1)

3 (9.4)

Fever

0

5 (15.6)

1 (3.1)

0

1 (3.1)

6 (18.8)

Oral Mucositis

0

4 (12.5)

1 (3.1)

0

1 (3.1)

5 (15.6)

Diarrhea

0

3 (9.4)

0

0

0

3 (9.4)

  1. The most commonly seen grade 3/4 haematological adverse events were neutropenia in 22 (68.8%) and leukopenia in 13 (40.6%) patients. The grade 3/4 non-haematological toxicities included peripheral neuropathy in four (12.5%) patients and febrile neutropenia in three (9.4%) patients